Status:
COMPLETED
Epidemiological EMESIS-Registry
Lead Sponsor:
iOMEDICO AG
Collaborating Sponsors:
Arbeitsgemeinschaft fur Internistische Onkologie
ASORS
Conditions:
Antiemetic Therapy
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on...
Eligibility Criteria
Inclusion
- Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
- start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given \>= 24 months ago.
- Compliance with registry procedures
- Age \>= 18 years
- WHO Performance Status of 0 or 1 (Karnofsky-Index \>= 70%)
- Life expectancy of at least 12 weeks
- Signed and dated informed consent before the start of the registry
Exclusion
- Mentally incapable or incompliant patients
- Last chemotherapy \<= 24 months (if pretreated)
- Known hypersensitivity to antiemetic medication
- unability of the patient to be treated with oral medication
- pregnancy or lactation period
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
1035 Patients enrolled
Trial Details
Trial ID
NCT00911222
Start Date
October 1 2008
End Date
August 1 2009
Last Update
December 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
iOMEDICO AG
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79108